HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2024-04-18FDA Approved: TRIUMEQ PD — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TRIUMEQ PD (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare. This result…
-
FDA approval · 2024-04-18FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for JULUCA (dolutegravir and rilpivirine) submitted by ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2024-04-17Clinical Trial Update: ART First-line Treatment Durability in Russia
A completed clinical trial update reports on first-line ART durability in people with HIV-1 infection in Russia, with results posted in 2024…
-
CLINICAL_TRIALS trial_result · 2024-04-17Clinical Trial Update: Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV [NA]
A completed feasibility trial assessed mindfulness-based stress reduction for Black women living with HIV; results posted in 2024.
-
FDA approval · 2024-04-05FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for DOVATO (dolutegravir and lamivudine) from ViiV Healthcare Company.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-04-03FDA Approved: APTIVUS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for APTIVUS (tipranavir) from Boehringer Ingelheim Pharmaceuticals, Inc., updating the drug’s la…
-
FDA approval · 2024-04-03FDA Approved: MYTESI — Supplemental Application (Napo Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Mytesi (crofelemer) from Napo Pharmaceuticals, confirming/expanding its regulatory approval …
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease [Phase 1]
Phase 1 trial examining the effect of N-803 on B cell follicles in antiretroviral-treated HIV disease has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2024-04-01Clinical Trial Update: Randomized Pilot Study of a mHealth App for Ambivalent Smokers Living With HIV [NA]
A randomized pilot study evaluated a mobile health app for ambivalent smokers living with HIV; results posted after completion.
-
FDA approval · 2024-03-28FDA Approved: ABACAVIR — Supplemental Application (Cipla USA Inc.)
The FDA approved a supplemental application for Abacavir submitted by Cipla USA Inc.
-
FDA approval · 2024-03-28FDA Approved: ABACAVIR — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for abacavir sulfate filed by Rising Pharma Holdings, Inc.
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS [Phase 4]
Phase 4 clinical trial update evaluating COVID-19 CoronaVac in patients with autoimmune rheumatic diseases and HIV/AIDS; completed.
-
FDA approval · 2024-03-21FDA Approved: NEVIRAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Nevirapine from Mylan Pharmaceuticals Inc., resulting in a generic Nevirapine product under the …
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women
This clinical trial update announces completion and results posting for a study evaluating pre-exposure prophylaxis (PrEP) in pregnant and b…
-
FDA approval · 2024-03-15FDA Approved: EDURANT PED — Original Application (Janssen Products, LP)
FDA approved EDURANT PED (rilpivirine hydrochloride) for HIV-1 infection in pediatric patients, establishing the original pediatric indicati…
-
FDA approval · 2024-03-15FDA Approved: EDURANT — Supplemental Application (Janssen Products, LP)
FDA approved a supplemental application for EDURANT (rilpivirine hydrochloride) submitted by Janssen Products, LP.
-
EMA withdrawal · 2024-03-14EMA Withdrawn: Sustiva (efavirenz) — Bristol-Myers Squibb Pharma EEIG
Sustiva (efavirenz) has been withdrawn from the EU market.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants [Phase 1]
Phase 1 trial assessing relative bioavailability and food effects of a fixed-dose combination of GSK3640254 and dolutegravir in healthy part…
-
FDA approval · 2024-03-09FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Teva's fixed-dose combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate for…
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine [Phase 4]
Phase 4 clinical trial of a bictegravir/emtricitabine/tenofovir alafenamide plus doravirine regimen for HIV-1 infection has completed with r…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy [Phase 1, Phase 2]
A phase 1/2 trial evaluated strategies to reduce the residual reservoir of HIV-1 infected cells in patients on antiretroviral therapy; the s…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir [Phase 3]
A Phase 3 trial assessing switch from protease inhibitor/ritonavir to a generic single-tablet regimen of tenofovir alafenamide/emtricitabine…
-
CLINICAL_TRIALS research · 2024-02-28Clinical Trial Update: Studying Topiramate for Re-Activating the HIV-1 Reservoir [Phase 1, Phase 2]
Clinical trial update investigating topiramate to reactivate the HIV-1 reservoir in Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial [Phase 4]
A Phase 4 randomized trial comparing 2DR versus 3DR in people with HIV-1 infection is currently recruiting
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Adherence to HIV Treatment Postpartum: The Implications of Transitions Among Women Living With HIV in South Africa [NA]
Clinical trial completed; study examined adherence to HIV treatment postpartum among women living with HIV in South Africa, with results pos…